1. Scrip
  2. >>Therapy Areas

Jazz Poised To Hold Onto Strong Sleep Disorder Position

 
• By Leah Samuel and Jessica Merrill

Jazz detailed Phase III data on a next-generation narcolepsy drug that could extend the life of its successful Xyrem franchise. The launch of Sunosi also is underway.  

Jazz Pharmaceuticals PLC detailed positive Phase III data on a next-generation narcolepsy drug that could extend the company's solid position in the space at the World Sleep meeting on 26 September. The company is hoping to file a new drug application for the product, JZP-258, by the end of the year, after meeting with the US Food and Drug Administration.

JZP-258 is positioned as a safer version of Jazz's blockbuster Xyrem (sodium oxybate). It is being developed for the treatment...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapy Areas

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

BioNTech To Buy mRNA Rivals CureVac

 
• By Andrew McConaghie

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?